Glucagon-like peptide-1 (GLP-1) receptor agonists and other anti-obesity pharmacotherapies are widely acknowledged as supplementary alternatives for weight management in women with polycystic ovarian syndrome (PCOS) when lifestyle modifications prove inadequate. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.